At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 31 enrolled
Drug / intervention
10% liquid formulation of human immunoglobulinbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
In Brief
A Phase 3 clinical trial evaluating 10% liquid formulation of human immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy. Completed, enrolled 31 participants across 22 sites in 5 countries.
Detailed Summary
The objective of this study is to demonstrate the efficacy and safety of Privigen in subjects with CIDP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Finland, France, Germany, Poland
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartNov 2010
Primary CompletionNov 2011
TodayJul 2026
First PostedAug 19, 2010
Enrollment StartNov 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.9 years ago
Interventions
10% liquid formulation of human immunoglobulinbiological